Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while the S&P 500 has gained 41%. The gene-editing specialist has, no doubt, faced some headwinds.However, important catalysts could double its stock price by 2030. For those keeping score at home, that would amount to a compound annual growth rate of about 14.9%, well above the market's historical average returns. CRISPR Therapeutics' focus on gene editing has some advantages and disadvantages. On the one hand, its revolutionary techniques can allow researchers to create therapies for otherwise untreatable (or difficult-to-treat) conditions. CRISPR proved as much when it created and developed Casgevy, a one-time treatment that provides a functional cure for two genetic blood disorders: sickle cell disease and transfusion-dependent beta-thalassemia. CRISPR shares the rights to Casgevy together with Vertex Pharmaceuticals.Continue reading
Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while the S&P 500 has gained 41%. The gene-editing specialist has, no doubt, faced some headwinds.
However, important catalysts could double its stock price by 2030. For those keeping score at home, that would amount to a compound annual growth rate of about 14.9%, well above the market's historical average returns.
CRISPR Therapeutics' focus on gene editing has some advantages and disadvantages. On the one hand, its revolutionary techniques can allow researchers to create therapies for otherwise untreatable (or difficult-to-treat) conditions. CRISPR proved as much when it created and developed Casgevy, a one-time treatment that provides a functional cure for two genetic blood disorders: sickle cell disease and transfusion-dependent beta-thalassemia. CRISPR shares the rights to Casgevy together with Vertex Pharmaceuticals.
